CU20120121A7 - Procedimiento de activación y conjugación de biomoléculas - Google Patents

Procedimiento de activación y conjugación de biomoléculas

Info

Publication number
CU20120121A7
CU20120121A7 CU2012000121A CU20120121A CU20120121A7 CU 20120121 A7 CU20120121 A7 CU 20120121A7 CU 2012000121 A CU2012000121 A CU 2012000121A CU 20120121 A CU20120121 A CU 20120121A CU 20120121 A7 CU20120121 A7 CU 20120121A7
Authority
CU
Cuba
Prior art keywords
biomolecules
conjugation
activation
procedure
producing
Prior art date
Application number
CU2012000121A
Other languages
English (en)
Inventor
Jens H Vogel
Chi Shung Brian To
Carolina Lucia Bianco
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of CU20120121A7 publication Critical patent/CU20120121A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/02—Reverse osmosis; Hyperfiltration ; Nanofiltration
    • B01D61/025—Reverse osmosis; Hyperfiltration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/10—Cross-flow filtration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/16—Diafiltration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Water Supply & Treatment (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a un procedimiento para producir un conjugado de biomoléculas en el que el procedimiento está integrado en una sola operación unitaria.
CU2012000121A 2010-02-21 2012-08-21 Procedimiento de activación y conjugación de biomoléculas CU20120121A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30651310P 2010-02-21 2010-02-21
PCT/US2011/025592 WO2011103531A1 (en) 2010-02-21 2011-02-21 Method for Activation and Conjugation of Biomolecules

Publications (1)

Publication Number Publication Date
CU20120121A7 true CU20120121A7 (es) 2013-01-30

Family

ID=44483343

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2012000121A CU20120121A7 (es) 2010-02-21 2012-08-21 Procedimiento de activación y conjugación de biomoléculas

Country Status (34)

Country Link
US (1) US9254336B2 (es)
EP (1) EP2536399B1 (es)
JP (1) JP5726915B2 (es)
KR (1) KR101776976B1 (es)
CN (2) CN105664175B (es)
AU (1) AU2011217794B2 (es)
BR (1) BR112012020855B8 (es)
CA (1) CA2790401C (es)
CL (1) CL2012002306A1 (es)
CO (1) CO6592111A2 (es)
CR (1) CR20120437A (es)
CU (1) CU20120121A7 (es)
CY (1) CY1122711T1 (es)
DK (1) DK2536399T3 (es)
EA (1) EA201290804A1 (es)
EC (1) ECSP12012112A (es)
ES (1) ES2769629T3 (es)
GT (1) GT201200244A (es)
HR (1) HRP20192164T1 (es)
HU (1) HUE047661T2 (es)
IL (1) IL221447A (es)
LT (1) LT2536399T (es)
MX (1) MX2012009674A (es)
NZ (1) NZ601905A (es)
PE (1) PE20130003A1 (es)
PH (2) PH12012501664A1 (es)
PL (1) PL2536399T3 (es)
PT (1) PT2536399T (es)
RS (1) RS59827B1 (es)
SG (1) SG183309A1 (es)
SI (1) SI2536399T1 (es)
UA (1) UA115221C2 (es)
WO (1) WO2011103531A1 (es)
ZA (2) ZA201206215B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE481323A (es) * 1947-04-10
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
JP2016531915A (ja) 2013-08-28 2016-10-13 ステムセントリックス， インコーポレイテッド 部位特異的抗体コンジュゲーション方法および組成物
AU2014346792A1 (en) 2013-11-06 2016-06-02 Abbvie Stemcentrx Llc Novel anti-claudin antibodies and methods of use
KR20160097336A (ko) 2013-12-12 2016-08-17 스템센트알엑스 인코포레이티드 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법
EP3107576A4 (en) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60335383D1 (de) * 2002-07-15 2011-01-27 Univ Texas Antikörper mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen
US7384909B2 (en) 2002-07-15 2008-06-10 Board Of Regents, The University Of Texas System Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents
KR101031206B1 (ko) 2002-12-31 2011-04-27 넥타르 테라퓨틱스 말레암산 중합체 유도체 및 이의 바이오컨쥬게이트
US20050175619A1 (en) * 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
DK2371856T3 (en) * 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
US20070173634A1 (en) 2006-01-24 2007-07-26 Olsson Nils U Methods for one-step purification of organic polymers using tangential flow filtration
US20080220448A1 (en) * 2006-09-01 2008-09-11 Blincko Stuart J Antigenic protein conjugates and process for preparing same
US8207298B2 (en) 2008-05-01 2012-06-26 Archemix Corp. Methods of separating biopolymer conjugated molecules from unconjugated molecules
BR112012001814A8 (pt) * 2009-07-27 2018-02-06 Baxalta GmbH Conjugados de proteína de coagulação sanguínea
SG181628A1 (en) * 2009-12-22 2012-07-30 Celldex Therapeutics Inc Vaccine compositions

Also Published As

Publication number Publication date
MX2012009674A (es) 2012-09-07
CN105664175A (zh) 2016-06-15
CA2790401A1 (en) 2011-08-25
CY1122711T1 (el) 2021-03-12
WO2011103531A1 (en) 2011-08-25
EA201290804A1 (ru) 2013-03-29
ECSP12012112A (es) 2012-10-30
PH12012501664A1 (en) 2012-10-22
CA2790401C (en) 2018-05-29
HRP20192164T1 (hr) 2020-03-06
EP2536399A4 (en) 2016-02-24
CN102970988A (zh) 2013-03-13
LT2536399T (lt) 2020-03-10
SI2536399T1 (sl) 2020-02-28
ZA201206215B (en) 2014-10-29
JP2013520441A (ja) 2013-06-06
EP2536399B1 (en) 2019-11-20
ES2769629T3 (es) 2020-06-26
SG183309A1 (en) 2012-09-27
KR20120120966A (ko) 2012-11-02
PL2536399T3 (pl) 2020-06-29
GT201200244A (es) 2014-09-02
CO6592111A2 (es) 2013-01-02
CN105664175B (zh) 2019-07-23
AU2011217794B2 (en) 2015-01-29
PH12016501602A1 (en) 2017-06-05
CL2012002306A1 (es) 2013-01-18
PT2536399T (pt) 2020-02-06
NZ601905A (en) 2014-09-26
CR20120437A (es) 2012-12-07
IL221447A (en) 2015-09-24
KR101776976B1 (ko) 2017-09-08
ZA201405941B (en) 2018-05-31
JP5726915B2 (ja) 2015-06-03
CN102970988B (zh) 2016-03-16
BR112012020855A2 (pt) 2017-08-29
HK1182330A1 (zh) 2013-11-29
PE20130003A1 (es) 2013-01-19
US20130040362A1 (en) 2013-02-14
US9254336B2 (en) 2016-02-09
EP2536399A1 (en) 2012-12-26
RS59827B1 (sr) 2020-02-28
AU2011217794A1 (en) 2012-09-20
BR112012020855B8 (pt) 2021-05-25
HK1225652A1 (zh) 2017-09-15
UA115221C2 (uk) 2017-10-10
HUE047661T2 (hu) 2020-05-28
IL221447A0 (en) 2012-10-31
BR112012020855B1 (pt) 2021-05-04
DK2536399T3 (da) 2020-02-10

Similar Documents

Publication Publication Date Title
CR20120184A (es) Anticuerpos monoclonales frente a progastrina y su usos
CR20120437A (es) Procedimiento de activación y conjugación de biomoléculas
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
ECSP10010295A (es) Formulacion de anticuerpo
CR20120215A (es) Anticuerpos contra csf-1r humano y usos de los mismos
CO6551674A2 (es) Anticuerpos anti-her3 y usos de los mismo
GB201103836D0 (en) Conjugation process
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
ECSP14000329A (es) Moléculas que son anticuerpos con especificidad por ox40 humano
CO7151488A2 (es) Anticuerpos de reacción cruzada anti-jagged1/jagged 2, anticuerpos anti-jagged activables y métodos de uso de los mismos
MX338078B (es) Cristales de anticuerpos anti-esclerostina y formulaciones de los mismos.
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
BR112014006822A2 (pt) proteínas de ligação ao antígeno cd27l
UA108199C2 (uk) АНТИТІЛО ПРОТИ α5β1 І ЙОГО ЗАСТОСУВАННЯ
CR20120036A (es) Terapia de combinación de un anticuerpo cd20 afucosilado y bendamustina
TWD163459S (zh) 錶用機心
CL2013001129A1 (es) Composicion que comprende una celula madre gbm6-ad de glioblastoma purificada; metodo de generacion de anticuerpos especificos para gbm6-ad; dicho anticuerpo; metodo para producir una vacuna de celulas dendriticas; y su uso para el tratamiento de cancer.
ES2421956A1 (es) Nueva forma cristalina de sulfato de sitagliptina
ECSP11011376A (es) Dispositivo y procedimiento para la verificación y para el análisis cuantitativo de analitos, particularmente de micotoxinas
UY34902A (es) Forma cristalina de un derivado de indolinona y su uso
ECSP11011190A (es) Anticuerpos monoclonales anti-rhd
CL2012003371A1 (es) Compuestos intermediarios de la síntesis de agomelatina; y el procedimiento de obtención de agomelatina a partir de dichos compuestos intermediarios
BR112012000398A2 (pt) processo para preparação de uma partícula de perfume.
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
CL2009000463A1 (es) Procedimiento de preparacion de combretastatina por enriquecimiento de un alqueno y posterior acoplamiento con l-serina en presencia de t3p.